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Abstract
Objectives—A number of case reports have been published describing a possible association
between isotretinoin (Accutane) and inflammatory bowel disease (IBD). We critically appraised the
published literature on this association to assess whether the current literature supports a causal
relationship between isotretinoin and IBD.
Methods—We systematically searched the literature for case reports, case series, and clinical trials
assessing the association between isotretinoin and IBD. We then applied the nine Bradford Hill
criteria in order to evaluate causality of this association.
Results and discussion—We identified 12 case reports and 1 case series that reported an
association between isotretinoin use and subsequent development of IBD. Cases occurred in 7
different countries over a 23 year time period (1986 to 2008). Cases differed with respect to dose of
isotretinoin reported, duration of treatment prior to development of disease, whether disease
developed on or off medication, and clinical presentation of disease. To date, no prospective or
retrospective case control or cohort studies have examined the relationship between isotretinoin
exposure and the outcome of IBD. An estimated 59 coincident cases of IBD would be expected in
Accutane users each year, assuming no increased risk. Application of the Bradford-Hill criteria
reveals that the temporality criterion of causation is fulfilled, though a number of alternative
explanations may account for the observed sequence of events seen in case reports. Strength,
specificity, and consistency of the association are lacking.
Conclusions—Current evidence is insufficient to confirm or refute a causal association between
isotretinoin and IBD. Additional prospective or well-designed retrospective (e.g. case-control)
pharmacoepidemiologic studies are needed to definitively establish causality.
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Introduction
In a recent court case in New Jersey, a jury awarded $12.9 million to three patients who were
diagnosed with inflammatory bowel disease (IBD) after being treated with the acne medication
Accutane (isotretinoin). A number of similar multimillion dollar lawsuits preceded this one.
Accutane was FDA-approved for the treatment of severe recalcitrant nodular acne in 1982 by
Roche. Subsequently, a number of case reports of this association were published in the post
marketing period(1-6), and the development of IBD is now listed as a warning in the package
insert for Accutane(7). In addition to individual case reports, Reddy et al. have recently
published a review of the FDA MedWatch reports of IBD cases occurring in association with
isotretinoin use(8). Although the possibility that isotretinoin may predispose to the
development of IBD is a cause for serious concern, the published case reports and case series,
as well as related court decisions must be interpreted with caution.
Case reports are essential in identifying possible adverse drug reactions and are thus
“hypothesis-generating.” However, such reports are subject to a number of flaws, including
recall bias, publication bias, incomplete and subjective presentation of case details (by both
patients and physicians), and lack of follow-up. Because of such biases, case reports may lead
readers to assume causation and to overestimate the risks in similar patients and the population
at large.
In order to evaluate the whether the reported association between isotretinoin and IBD is causal,
we first searched the published literature to identify all relevant papers and case reports. Next,
we performed a critical appraisal of this literature using the criteria developed by Sir Austin
Bradford-Hill to evaluate whether the relationship between two factors might be causal. The
Bradford-Hill criteria, first established in 1965, are comprised of nine components: strength,
consistency, specificity, temporality, biologic gradient, plausibility, coherence, experimental
evidence, and analogy(9). While the presence or absence of any one criterion is insufficient to
confirm or refute causality, when an association fulfills a preponderance of these criteria, a
case for an etiological connection can be made.
Summary of case reports
Twelve case reports (1-6,10-15) and 1 case series (16) were identified via a systematic search
strategy. Results are summarized in Table 1. In total, 15 cases were reported in 7 different
countries over a 23 year time period (1986 to 2008). In addition, there were 85 cases reported
in the FDA MedWatch analysis from 1997 to 2002(8). Cases developed at a range of doses
(20mg–80mg per day), and several of the cases were diagnosed after therapy with isotretinoin
had been discontinued(2,5,14,16). Two cases resolved after Accutane was discontinued(12,
15). Five of the individual case reports did not report a definitive diagnosis of IBD (11-15).
Causal criteria
1) Strength
Strength is defined by the size of the association as measured by appropriate effect measures
(risk difference, relative risk, odds ratio, or equivalent). The stronger the association, the more
likely a relationship is causal. No published observational or interventional studies have
Crockett et al. Page 2













adequately measured the strength of the association between isotretinoin and IBD in a
quantitative way.
Case reports and case series include only individuals that had both the exposure (isotretinoin)
and outcome (IBD). Additional data are required to estimate the strength of exposure-outcome
relationships. Specifically, the number of individuals treated who did not develop the outcome,
and the baseline incidence of disease in untreated individuals are needed to calculate measures
of effect such as risk ratios or odds ratios.
Despite the incomplete data, it is instructive to estimate the strength of this potential association
using population-based estimates of isotretinoin use and IBD incidence to complete the missing
cells of a traditional 2×2 table (Figure 1). Assuming 1) a background incidence of IBD in the
US of approximately 45,000 cases per year(17,18) 2) the number of persons taking isotretinoin
is approximately 400,000 per year(19), and 3) the total US population is approximately 306
million(20), the expected number of cases of IBD among isotretinoin users would be 59 cases
per year (if there were no association between isotretinoin and IBD), or 0.01% of Accutane
users. If more than 59 cases per year were observed in isotretinoin users, this would suggest a
positive relationship between isotretinoin use and IBD. However FDA MedWatch reports
include an average of only 14 cases per year(8). Although MedWatch reports are certainly
subject to under-reporting (21),the published number of cases do not support a strong
association.. Importantly, this exercise demonstrates that a certain number of cases of IBD are
likely to develop in isotretinoin users simply on the basis of chance. It is possible, therefore,
that the cases reported in the literature might simply be reflecting the chance co-incidence of
IBD and isotretinoin.
If isotretinoin use is more common in IBD sufferers, that would also contribute to the strength
of the association. Though no case control studies have been performed examining this
relationship, one retrospective study of 306 IBD cases in Italy failed to demonstrate any prior
exposures to isotretinoin.(22)
2) Consistency
Consistency refers to whether the observed association has been repeatedly observed in
different persons and different settings. For example, at the time that Hill established
thesecriteria, there were a total of 29 retrospective and 7 prospective reports describing the
association between smoking and lung cancer, each reaching the same conclusion irrespective
of study design. Consistency provides reassurance that the association is not due to chance or
systematic bias.
Though multiple case reports of this association have been published in various geographic
areas, a consistent pattern of disease occurrence has not emerged. Case reports differ with
regards to duration of treatment, lag time between initiation of treatment and development of
disease, whether symptoms developed on or off therapy, and clinical features of disease.
However, as discussed above, the association between isotretinoin and IBD has not been
adequately measured in any studies; therefore, consistency of effect measures is impossible to
establish at this point in time.
3) Specificity
Specificity refers to whether an exposure leads to a specific outcome. For example, the link
between the diet drug combination phentermine/fenfluramine and valvular heart disease in
young women fulfills this criterion. In contrast, isotretinoin has protean effects(23) including
teratogenicity, effects on bone mineral density, hearing and visual disturbances, and
depression..
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Furthermore, both CD and UC have been reported with regards to this association, with
comparable frequency. It is well recognized that CD and UC are distinct clinical entities that
differ with respect to disease activity, pathology, and (presumptively) etiopathogenesis. Other
forms of colitis have also been reported including granulomatous colitis(13), and collagenous
colitis(14). The fact that one exposure has been linked to several outcomes indicates lack of
specificity. Nevertheless, specificity is considered the weakest of all the Hill’s criteria. Indeed,
tobacco has been demonstrated to cause a number of diseases, and illnesses such as lung cancer
have multiple predisposing factors in addition to smoking. Thus, the absence of specificity
does not preclude a causal relationship.
4) Temporality
In a temporal relationship, the cause (i.e. isotretinoin) must precede the outcome (i.e. onset of
IBD). Such a temporal relationship supports, but does not confirm, a causal relationship.
However, lack of a temporal relationship clearly refutes causality: an exposure that occurs after
the onset of disease clearly did not cause the disease.
Taken at face value, a temporal relationship exists between isotretinoin use and IBD onset, as
evidenced by the numerous case reports and case series. However, we propose several, non-
causal explanations for the observed temporal relationship. First, the association may be due
to confounding based on age. The peak age of IBD occurrence is in early adulthood, while the
peak age of isotretinoin use is age 13–24 (Figure 2)(19). Therefore, in the absence of causation,
most cases of IBD developing in persons who also have acne and are prescribed Accutane will
occur in this order.
In addition, the biological onset of IBD and initial symptoms often occur 1 year (or longer)
prior to diagnosis. Therefore, as has been suggested by other authors(6,8), it is possible in some
cases that although disease diagnosis may have occurred after exposure to isotretinoin, the
disease onset may actually have preceded isotretinoin therapy (i.e. isotretinoin was given to
persons with sublinical IBD)(Figure 3). We must also consider the possibility of reverse
causation: that IBD resulted in exposure to isotretinoin. Pyoderma faciale is a dermatologic
condition that may mimic severe acne, but is in fact a known extra-intestinal manifestation of
IBD that may precede its diagnosis (Figure 4)(24). Neutrophilic dermatoses such as Sweet’s
syndrome may also associated with IBD(25). It is possible that some cases of this association
occur in patients who’s underlying IBD (as manifested by these acne-like skin conditions)
preceded isotretinoin use, and thus the observed temporal relationship was inverted.
Another component of temporality includes whether the adverse event abates after withdrawal
of medication and recurs with reintroduction of medication. This pattern has been observed in
some case reports(12), however, it is difficult to interpret for a relapsing and remitting condition
such as IBD. The natural course of the disease may be mistaken for results of reintroduction
and withdrawal of isotretinoin. Also, the observation that symptoms resolve upon
discontinuation of isotretinoin therapy, in most cases, would be complicated by concomitant
initiation of IBD therapy (e.g. corticosteroids), another example of confounding. Furthermore,
the observation that symptoms return upon reintroduction of isotretinoin is complicated by the
fact that reintroduction is likely to occur during periods of disease remission. Based on the
natural history of the disease itself, independent of any effects of isotretinoin, some of these
patients will experience a recurrence of symptoms (Figure 3).
5) Biologic gradient
The biologic gradient criterion refers to whether a dose-response relationship is present: if an
increasing dose of the exposure corresponds to an increase in incidence and/or severity of
effects, this supports a causal relationship. For example, acetaminophen-induced
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hepatotoxicity fulfills this criterion, with higher doses corresponding to worsened risk of liver
failure. Evidence of a biological gradient is supported by 3 cases of persons who were
diagnosed with IBD shortly after increasing their dose of isotretinoin (8,12,13). However, there
are also case reports of this association in persons taking relatively low doses of isotretinoin
(20 mg/day(6) and 30 mg/day(3)), as well as in patients who had discontinued isotretinoin prior
to the presentation of IBD(2,5,14,16). Interestingly, an early study of Accutane’s adverse
effects demonstrated an inverse dose-response relationship with regards to gastrointestinal
symptoms(23). Therefore, at this point in time, the evidence of a biological gradient is
inconclusive.
6) Plausibility
This refers to whether the observed association is biologically plausible. Given that the etiology
of IBD is largely unknown, it is difficult to assess the plausibility of isotretinoin as a trigger
of IBD. In fact, the mechanistic studies that are available in the published literature could
support a beneficial effect of vitamin A derivatives in regards to the development and
perpetuation of IBD. For example, a key factor implicated in the pathogenesis of IBD is
impaired barrier function of the intestinal epithelium. Retinoic acid, a form of vitamin A, has
been shown to enhance barrier function by increasing expression of numerous tight junction
proteins such as occludin, claudin-1, claudin-4, and zonula occludens-1(26). Furthermore, from
the standpoint of immune function, retinoic acid has been shown to be capable of inhibiting
pro-inflammatory interleukin-17-producing T helper cell (Th17) responses, while augmenting
anti-inflammatory regulatory T cell induction(27). Such responses would be more likely to
prevent the development of IBD, as opposed to trigger it. Nevertheless, retinoids have
pleiotropic effects, including natural killer T-cell stimulation, B-cell differentiation, disruption
of glycoprotein synthesis and epithelial tissue growth, apoptosis, and alteration of cytokines
(12,28,29). Therefore, though speculative, the association between isotretinoin and IBD
remains biologically plausible, though beneficial effects could be postulated as well.
7) Coherence
This principle states that a causal relationship should not contradict the known facts of the
natural history and biology of the disease in question. One threat to coherence is that several
reports have been published of use of isotretinoin in patients with known pre-existing IBD who
did not experience exacerbations of disease(30-35); if isotretinoin causes IBD, we might expect
that exposure could also lead to flares of known disease. Furthermore, while the number of
prescriptions for Accutane in the US rose rapidly in the 1990s(19), rates of IBD have remained
relatively constant during the same time period(18,36). However, as there are many unknowns
regarding the etiology and pathophysiology of IBD, a causal association would be difficult to
refute on the basis of lack of coherence.
8) Experimental evidence
This criterion refers to whether evidence in humans or other species exists to corroborate the
connection. No human experiments have addressed this question, and we were unable to find
published evidence of colitis developing in animals exposed to isotretinoin or similar
compounds. Experimental evidence also refers to whether the outcome can be prevented or
ameliorated by an appropriate experimental regimen. Since the mechanisms of isotretinoin are
largely unknown and no single ‘antidote’ exists, such experiments are not possible.
9) Analogy
Analogy refers to the effect of similar factors. There are no known medication triggers of IBD
from which to draw analogies, and no other retinoid compounds have been linked to IBD. Nor
can analogies be drawn from isotretinoin’s proposed mechanisms of acne amelioration
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(inhibition of sebaceous gland function and keratinization)(37) and teratogenicity (impaired
cephalic neural-crest cell activity)(38), which seem distinct from the putative mechanism(s)
of IBD, which involves disruption of bowel mucosa integrity and induction of autoimmunity.
Conclusion
In conclusion, the only evidence to support a causal association between Accutane and IBD
consists of isolated case reports. These reports support a possible temporal association between
isotretinoin and the development of IBD, though such observations may have resulted from
chance, confounding, bias, and misrepresentation of the natural history of IBD. A causal
relationship remains biologically plausible, but beneficial effects of vitamin A derivatives on
intestinal injury have been reported as well. None of the other commonly accepted causal
criteria are met. The lack of evidence does not necessarily indicate lack of a causal connection.
However, in the absence of observational studies which assess the strength and consistency of
the association and/or experimental studies which confirm such an association, any conclusions
about a causal link are premature at best, and future studies are needed to enable a more rigorous
assessment about causality. Until such time as that becomes possible, it is difficult to provide
any substantive assessment of the IBD-associated risks of isotretinoin use. Therefore, while it
remains possible that an association between isotretinoin and IBD will eventually be
established, current published evidence is insufficient to support this claim.
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A hypothetical cohort study of the entire US population is represented in this model 2×2 table.
The time period at risk is 1 year. Equal rates of IBD in both exposed persons (“received
isotretinoin”) and unexposed persons (“No isotretinoin”) would correspond to an incidence
rate ratio of 1 (i.e. no causation). We made assumptions about the annual incidence of IBD,
the number of persons exposed to isotretinoin per year, and the size of the US population using
the best available data. We then calculated the expected number of new cases of IBD per year
in those taking isotretinoin assuming no causation (calculation below). The number of cases
per year in those taking isotretinoin would have to be greater than 59 in order to support a
causal association.
Where x = expected cases with exposure
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IBD: inflammatory bowel disease; py: person years
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Graph of the peak ages of isotretinoin prescriptions and incidence of Crohn’s disease
demonstrating the normal temporal sequence of development of IBD in Accutane users, and
evidence for confounding based on age as an explanation for the temporal association between
drug and disease.
Figure based on data from Loftus et al., Gastroenterology 1998;114(6) 1161-8 (17) and
Wysowski et al., J Am Acad Dermatol 2002; 46(4) 505-9 (19)
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Diagram of a possible non-causal sequence of events leading to an observed temporal
relationship between isotretinoin use and inflammatory bowel disease. Because of delays in
the initial diagnosis of IBD, subclinical onset of disease may precede the initial prescription
of isotretinoin. If isotretinoin is discontinued when IBD is initially diagnosed, and reintroduced
when disease activity is quiescent, subsequent flares of disease typical of the natural history
of IBD could be mistaken for effects of re-exposure to the drug.
IBD: inflammatory bowel disease
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Appearance of pyoderma faciale, an extraintestinal manifestation of inflammatory bowel
disease that may mimic acne.
Reprinted with permission from Cutis. 2008;81:488-490. ©2008, Quadrant HealthCom Inc.
(39)
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